Page last updated: 2024-11-05

levocarnitine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Levocarnitine is the L-isomer of carnitine, a naturally occurring quaternary ammonium compound that plays a crucial role in fatty acid metabolism. It is synthesized in the body from lysine and methionine, and is also obtained through dietary sources like red meat, poultry, and dairy products. Levocarnitine facilitates the transport of long-chain fatty acids across the mitochondrial membrane, where they are oxidized to produce energy. It is involved in various physiological processes, including energy production, muscle function, and neurotransmission. Levocarnitine has been studied for its potential therapeutic effects in conditions such as cardiovascular disease, mitochondrial disorders, and exercise performance enhancement. However, its effectiveness in these areas is still under investigation. Levocarnitine is generally considered safe for consumption, but high doses can cause gastrointestinal side effects. It is also important to note that levocarnitine is a regulated substance in some countries.'
```

(R)-carnitine : The (R)-enantiomer of carnitine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10917
CHEMBL ID1149
CHEBI ID16347
SCHEMBL ID21970
MeSH IDM000596392

Synonyms (160)

Synonym
BIDD:GT0603
metina
gamma-trimethyl-beta-hydroxybutyrobetaine
levocarnitina [spanish]
carnitolo
(3-carboxy-2-hydroxypropyl)trimethyl-ammonium hydroxide, inner salt
levocarnitine [usan:inn]
levocarnitinum [latin]
karnitin
(r)-(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide
gamma-trimethyl-ammonium-beta-hydroxybutirate
1-propanaminium, 3-carboxy-2-hydroxy-n,n,n-trimethyl-, hydroxide, inner salt
(l-3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt
carrier
carnovis
einecs 208-768-0
lefcar
bdbm50037268
carnitor
CHEBI:16347 ,
(3r)-3-hydroxy-4-(trimethylammonio)butanoate
carnitene
(-)-carnitine
(-)-l-carnitine
carnitor sf
l-carnitine base
l-carnitine inner salt
smr000112475
MLS001332549
MLS001332550
1-propanaminium, 3-carboxy-2-hydroxy-n,n,n-trimethyl-, inner salt, (2r)-
carnitine (l-form)
l-(-)-carnitine
carnitine, (-)-
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, l-
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide,inner salt
1-propanaminium, 3-carboxy-2-hydroxy-n,n,n-trimethyl-, hydroxide, inner salt, (r)-
1-propanaminium, 3-carboxy-2-hydroxy-n,n,n-trimethyl-, inner salt, (r)-
carniking 50
(-)-(r)-3-hydroxy-4-(trimethylammonio)butyrate
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, l- (8ci)
drg-0211
carniking
carnilean
1-propanaminium, 3-carboxy-2-hydroxy-n,n,n-trimethyl-, inner salt, (2r)- (9ci)
levocarnitine
r-(-)-3-hydroxy-4-trimethylaminobutyrate
gamma-l-trimethyl-beta-hydroxybutyrobetaine
3-carboxy-2-hydroxy-n,n,n-trimethyl-1-propanaminium hydroxide, inner salt
541-15-1
(r)-carnitine
bicarnesine
l-gamma-trimethyl-beta-hydroxybutyrobetaine
C00318
vitamin b t
l-carnitine
vitamin bt
44985-71-9
3-carboxy-2-hydroxy-n,n,n-trimethyl-1-propanaminium
l-carnitine inner salt, synthetic, >=98%
DB00583
D02176
carnitor (tn)
levocarnitine (jan/usp/inn)
l carnitine
C-1985 ,
HMS2093J13
(r)-3-hydroxy-4-(trimethylammonio)butyrate
C0049
(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate
carnitine, l-
1-carnitine
BMSE000211
levocarnitine hcl
nsc-759132
CHEMBL1149 ,
oristar lch
carnitine dl-form hydrochloride
carnitine hcl
carnitine hydrochloride, dl-
nsc-741806
levocarnitina
(r)-(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt
nsc741806
(r)-3-hydroxy-4-trimethylammoniobutyrate
AKOS005267245
(3r)-3-hydroxy-4-(trimethylammonio)butanoate;l-carnitine
A829968
pharmakon1600-01505437
nsc759132
HMS2267H24
BCP9000830
0g389fzz9m ,
nsc 759132
unii-0g389fzz9m
levocarnitine [usan:usp:inn:ban]
levocarnitinum
hsdb 7588
1-propanaminium,3-carboxy-2-hydroxy-n,n,n-trimethyl-
levocarnitine [hsdb]
levocarnitine [mart.]
levocarnitine [jan]
levocarnitine [inn]
levocarnitine [usp-rs]
levocarnitine [orange book]
l-carnitine [fcc]
levocarnitine [who-dd]
levocarnitine [usan]
l-carnitine [vandf]
carnitine [mi]
levocarnitine [vandf]
levocarnitine [usp monograph]
levocarnitine [ep monograph]
S2388
gtpl4780
CCG-213241
HY-B0399
SCHEMBL21970
KS-1422
AB00919083_05
AB00919083_06
DTXSID4023208 ,
(2r)-3-carboxy-2-hydroxy-n,n,n-trimethyl-1-propanaminium inner salt
(r)-3-hydroxy-4-(trimethylammonio)butanoate
levocarnitine, united states pharmacopeia (usp) reference standard
levocarnitine, european pharmacopoeia (ep) reference standard
levocarnitine, pharmaceutical secondary standard; certified reference material
l-carnitin
carnipass 20
carnipass
3-hydroxy-4-trimethylammoniobutanoic acid
delta-carnitine
l-carnitine (levocarnitine)
l-carnitine,(s)
l-carnitin 100 microg/ml in acetonitrile
AS-11974
Q20735709
6-chloro-3-hydroxy(1h)indazole
(3r)-(-)-3-hydroxy-4-(trimethylammonio)butanoate
(-)-(r)-3-hydroxy-4-(trimethylammonio)butyrate, vitamin bt
EN300-6495783
levocarnitine oral solution
levocarnitine sf
r(-)-beta-hydroxy-gamma-(n,n,n-trimethylammonio)butyrate
levocarnitine (usp monograph)
levocarnil
3-hydroxy-4-(trimethylammonio) butanoate
levocarnitine (ep monograph)
levocarnitine (usan:usp:inn:ban)
levocarnitine (mart.)
l-carn
levocarnitine (usp-rs)
(r)-3-hydroxy-4-trimethylammoniobutanoate
levocarnitin
levocarnitinum (latin)
beta-hydroxy-gamma-n,n,n-trimethylammoniobutyrate
nefrocarnit
dtxcid903208
a16aa01
levocarnitine oral solution (suguar free) 1 g/10 ml

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
water-soluble vitamin (role)Any vitamin that dissolves in water and readily absorbed into tissues for immediate use. Unlike the fat-soluble vitamins, they are not stored in the body and need to be replenished regularly in the diet and will rarely accumulate to toxic levels since they are quickly excreted from the body via urine.
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
nootropic agentAny compound that improves mental functions such as cognition, memory, intelligence, motivation, attention, and concentration.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
carnitineAn amino-acid betaine that is butanoate substituted with a hydroxy group at position C-3 and a trimethylammonium group at C-4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (28)

PathwayProteinsCompounds
Oxidation of Branched-Chain Fatty Acids1122
Fatty Acid Metabolism1441
Carnitine Synthesis517
Ethylmalonic Encephalopathy1441
Glutaric Aciduria Type I1441
Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency)1441
Beta Oxidation of Very Long Chain Fatty Acids1013
Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty Acids1025
Adrenoleukodystrophy, X-Linked1013
Carnitine-Acylcarnitine Translocase Deficiency1013
Carnitine Palmitoyl Transferase Deficiency I1441
Long Chain Acyl-CoA Dehydrogenase Deficiency (LCAD)1441
Very-Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD)1441
Carnitine Palmitoyl Transferase Deficiency II1441
Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)1441
Trifunctional Protein Deficiency1441
L-Carnitine Degradation I410
L-carnitine biosynthesis014
mitochondrial L-carnitine shuttle04
Diet-dependent trimethylamine/trimethylamine N-oxide metabolism112
mitochondrial L-carnitine shuttle88
u03B3-butyrobetaine degradation123
L-carnitine degradation III724
L-carnitine degradation I417
D-carnitine degradation II011
L-carnitine degradation II124
L-carnitine biosynthesis623
carnitine shuttle34
carnitine degradation I210
Folic acid network070
Mitochondrial LC-Fatty Acid Beta-Oxidation08

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.41250.044717.8581100.0000AID485294
ATAD5 protein, partialHomo sapiens (human)Potency24.83440.004110.890331.5287AID504466; AID504467
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency44.66843.548119.542744.6684AID743266
gemininHomo sapiens (human)Potency12.99530.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 8Mus musculus (house mouse)Km0.06190.05392.40655.5000AID681386
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
carnitine metabolic process, CoA-linkedCarnitine O-acetyltransferaseHomo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidaseCarnitine O-acetyltransferaseHomo sapiens (human)
short-chain fatty acid metabolic processCarnitine O-acetyltransferaseHomo sapiens (human)
medium-chain fatty acid metabolic processCarnitine O-acetyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier family 22 member 8Mus musculus (house mouse)
acyl-CoA oxidase activityCarnitine O-acetyltransferaseHomo sapiens (human)
carnitine O-acetyltransferase activityCarnitine O-acetyltransferaseHomo sapiens (human)
carnitine O-octanoyltransferase activityCarnitine O-acetyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
basolateral plasma membraneSolute carrier family 22 member 8Mus musculus (house mouse)
mitochondrionCarnitine O-acetyltransferaseHomo sapiens (human)
mitochondrial inner membraneCarnitine O-acetyltransferaseHomo sapiens (human)
peroxisomeCarnitine O-acetyltransferaseHomo sapiens (human)
peroxisomal matrixCarnitine O-acetyltransferaseHomo sapiens (human)
endoplasmic reticulumCarnitine O-acetyltransferaseHomo sapiens (human)
cytosolCarnitine O-acetyltransferaseHomo sapiens (human)
peroxisomeCarnitine O-acetyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID49038Kinetic constants tested against pigeon breast carnitine acyltransferase1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
3-Amino-5,5-dimethylhexanoic acid. Synthesis, resolution, and effects on carnitine acyltransferases.
AID406580Cytotoxicity against human HL60 cells assessed as cell viability at >=5 uM after 24 hrs by MTT assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406581Cytotoxicity against human HL60 cells assessed as cell viability at <=2.5 uM by MTT assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1865552Substrate activity at human recombinant MBP-TMLD (42 to 421 residues) fusion protein expressed in Escherichia coli BL21-AI assessed as hydroxylated substrate formation at 500 uM in presence of alpha-ketoglutarate by proton 1D NMR spectroscopy2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Binding versus Enzymatic Processing of ε-Trimethyllysine Dioxygenase Substrate Analogues.
AID406596Cytotoxicity against human K562 cells assessed as necrosis at 1.25 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406597Cytotoxicity against human K562 cells assessed as necrosis at 1.25 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406594Cytotoxicity against human HL60 cells assessed as necrosis at 10 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406582Cytotoxicity against human K562 cells assessed as cell viability at >=5 uM after 24 hrs by MTT assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406585Cytotoxicity against human HL60 cells assessed as necrosis at 1.25 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406588Cytotoxicity against human HL60 cells assessed as necrosis at 2.5 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406924Cytotoxicity against human K562 cells assessed as necrosis at 10 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID1865536Binding affinity to human recombinant MBP-TMLD (42 to 421 residues) fusion protein expressed in Escherichia coli BL21-AI assessed as change in Gibbs free energy by isothermal titration calorimetry2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Binding versus Enzymatic Processing of ε-Trimethyllysine Dioxygenase Substrate Analogues.
AID1865537Binding affinity to human recombinant MBP-TMLD (42 to 421 residues) fusion protein expressed in Escherichia coli BL21-AI assessed as change in enthalpy by isothermal titration calorimetry2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Binding versus Enzymatic Processing of ε-Trimethyllysine Dioxygenase Substrate Analogues.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID49181Tested against neonatal rat cardiac myocyte carnitine palmitoyltransferase 21994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
3-Amino-5,5-dimethylhexanoic acid. Synthesis, resolution, and effects on carnitine acyltransferases.
AID386950Binding affinity to bovine serum albumin by fluorescence spectroscopy2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Study on the binding interaction between carnitine optical isomer and bovine serum albumin.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID406922Cytotoxicity against human K562 cells assessed as necrosis at 10 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406583Cytotoxicity against human K562 cells assessed as cell viability at <=2.5 uM by MTT assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID1865538Binding affinity to human recombinant MBP-TMLD (42 to 421 residues) fusion protein expressed in Escherichia coli BL21-AI assessed as change in entropy by isothermal titration calorimetry2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Binding versus Enzymatic Processing of ε-Trimethyllysine Dioxygenase Substrate Analogues.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID406593Cytotoxicity against human HL60 cells assessed as necrosis at 10 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406921Cytotoxicity against human K562 cells assessed as necrosis at 5 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406598Cytotoxicity against human K562 cells assessed as necrosis at 1.25 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406918Cytotoxicity against human K562 cells assessed as necrosis at 2.5 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406599Cytotoxicity against human K562 cells assessed as necrosis at 2.5 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406590Cytotoxicity against human HL60 cells assessed as necrosis at 5 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID406600Cytotoxicity against human K562 cells assessed as necrosis at 2.5 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID406923Cytotoxicity against human K562 cells assessed as necrosis at 10 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406586Cytotoxicity against human HL60 cells assessed as necrosis at 1.25 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID1865535Binding affinity to human recombinant MBP-TMLD (42 to 421 residues) fusion protein expressed in Escherichia coli BL21-AI by isothermal titration calorimetry2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Binding versus Enzymatic Processing of ε-Trimethyllysine Dioxygenase Substrate Analogues.
AID406592Cytotoxicity against human HL60 cells assessed as necrosis at 5 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406919Cytotoxicity against human K562 cells assessed as necrosis at 5 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406591Cytotoxicity against human HL60 cells assessed as necrosis at 5 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406589Cytotoxicity against human HL60 cells assessed as necrosis at 2.5 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406587Cytotoxicity against human HL60 cells assessed as necrosis at 2.5 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406584Cytotoxicity against human HL60 cells assessed as necrosis at 1.25 uM after 24 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID406920Cytotoxicity against human K562 cells assessed as necrosis at 5 uM after 48 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID386951Binding affinity to bovine serum albumin by fluorescence spectroscopy in presence of Fe3+2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Study on the binding interaction between carnitine optical isomer and bovine serum albumin.
AID49176Tested against neonatal rat cardiac myocyte carnitine palmitoyltransferase 11994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
3-Amino-5,5-dimethylhexanoic acid. Synthesis, resolution, and effects on carnitine acyltransferases.
AID681386TP_TRANSPORTER: uptake in mOat3-expressing oocytes2004Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 32, Issue:5
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
AID406595Cytotoxicity against human HL60 cells assessed as necrosis at 10 uM after 72 hrs by trypan blue staining2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's6 (37.50)29.6817
2010's6 (37.50)24.3611
2020's3 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.59 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index140.52 (26.88)
Search Engine Supply Index2.54 (0.95)

This Compound (68.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]